Tempus

Tempus is an AI-driven precision medicine company converting multimodal data (imaging, genomics, clinical records) into decision-support tools for oncology. Its flagship service is a genomic test battery (NGS DNA xT, liquid biopsy xF, RNA xR) validating tumor mutations and guiding appropriate therapy selection. Tempus stores and analyzes the industry's largest genomic-clinical database to suggest treatments based on similar patient genomic profiles. By 2025, Tempus generated $955 million in revenue (75% from diagnostics) with strong growth in reflex testing and multiple indications. The company ensures financial access for US patients via assistance programs.

Tempus does not offer a French-language interface. Test pricing is not public: it varies by test (DNA, RNA, liquid biopsy), cancer indication, and insurance acceptance. In the US, a financial assistance program covers patients without adequate coverage. An API enables integration to hospital EHRs. Tempus does not replace an oncologist: it is a therapy selection aid, not diagnosis. In Europe, the absence of official Social Security reimbursement complicates access; only certain academic hospital networks can negotiate entry. The main barrier for a European healthcare SME is access complexity and the absence of transparent pricing.